ArticleOncotarget2018
CXCR4: A new player in vestibular schwannoma pathogenesis.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Tumor Microenvironment in Sporadic Vestibular Schwannoma: A Systematic, Narrative Review.International journal of molecular sciences · 2023Pooled it
- Current molecular understanding of central nervous system schwannomas.Acta neuropathologica communications · 2025Review
- Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state.Nature communications · 2024Article
- Article
- Updates on Tumor Biology in Vestibular Schwannoma.Otolaryngologic clinics of North America · 2023Review
- The genetic landscape and possible therapeutics of neurofibromatosis type 2.Cancer cell international · 2023Review
- Multiplatform molecular analysis of vestibular schwannoma reveals two robust subgroups with distinct microenvironment.Journal of neuro-oncology · 2023Article
- Tumor Biology and Microenvironment of Vestibular Schwannoma-Relation to Tumor Growth and Hearing Loss.Biomedicines · 2022Review
- Current Status ofDiagnostics (Basel, Switzerland) · 2022Review
- A Critical Overview of Targeted Therapies for Vestibular Schwannoma.International journal of molecular sciences · 2022Review
- Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.Journal of neurological surgery. Part B, Skull base · 2022Review
- A Review of Drug Therapy in Vestibular Schwannoma.Drug design, development and therapy · 2021Review
- Analysis of ADAM9 regulation and function in vestibular schwannoma primary cells.BMC research notes · 2020Article
- An update on the CNS manifestations of neurofibromatosis type 2.Acta neuropathologica · 2020Review
- ADAM9: A novel player in vestibular schwannoma pathogenesis.Oncology letters · 2020Article
- [Frontiers in oncology · 2019Article
- Biomarkers in Vestibular Schwannoma-Associated Hearing Loss.Frontiers in neurology · 2019Review
- Combination of PET and CXCR4-Targeted Peptide Molecule Agents for Noninvasive Tumor Monitoring.Journal of Cancer · 2019Article
- The inflammatory microenvironment in vestibular schwannoma.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCXCR4 is a chemokine receptor that recruits blood stem cells and increases tumor cell growth and invasiveness. We examined CXCR4 expression in vestibular schwannomas (VS) from patients with and without neurofibromatosis type 2 (NF2) and correlated the levels with the patients' clinical characteristics. The aim was to determine whether CXCR4 can be used as a prognostic marker and as a target for systemic therapy.
resultsOverall, CXCR4 mRNA levels were 4.6-fold higher in VS versus control; the levels were 4.9-fold higher in NF2 patients and 4.2-fold higher in sporadic VS patients. IHC and WB showed heterogeneous protein expression, and CXCR4 was expressed mainly in S100-positive Schwann cells. There was no correlation between the CXCR4 protein levels and tumor extension. However, there was a trend towards correlation between higher expression levels and greater hearing loss. MATERIALS AND
methodsCXCR4 mRNA and protein levels were determined in VS samples (
conclusionsCXCR4 mRNA was overexpressed in VS relative to healthy vestibular nerves, and there was a trend towards higher CXCR4 expression levels being correlated with greater functional impairment. Thus, CXCR4 may be a prognostic marker of VS, and CXCR4 inhibition has potential as a systemic approach for the treatment of VS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.